Donna Headlee

Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma

Qin Ryan, Donna Headlee, Milin Acharya et al. · Journal of Clinical Oncology · 2005 · 414 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

Adrian M. Senderowicz, Donna Headlee, Sherman F. Stinson et al. · Journal of Clinical Oncology · 1998 · 408 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +15

Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms

Edward A. Sausville, Susan G. Arbuck, Richard A. Messmann et al. · Journal of Clinical Oncology · 2001 · 294 citations

Medicine, Oncology, Pharmacology +17

Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.

Eiichi Fuse, Hiromi Tanii, Noriaki Kurata et al. · PubMed · 1998 · 203 citations

Pharmacy, Pharmacokinetics, Pharmacology +10

Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study

EA Sausville, Donna Headlee, M Stetler-Stevenson et al. · Blood · 1995 · 166 citations · Full text

Medicine, Hematology, Oncology +8